Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
NCT ID: NCT04935853
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1350 participants
OBSERVATIONAL
2022-05-23
2040-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pancreatico-biliary Tumor Mutation Profiling in Bile Samples
NCT02893085
Microbiological Assessment of Bile in Patients Undergone to Endoscopic Retrograde Cholangiography (ERCP): the "Microbile Registry"
NCT06115564
Impact on Outcome of Early Endoscopic Extraction of Bile Duct Stones in Biliary Pancreatitis
NCT00505128
Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction
NCT05078801
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer
NCT03762837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Follow-up is retrospective only for patients operated on or diagnosed in the past for more than 10 years, and retro-prospective for operated patients or diagnosed in the past for less than 10 years.
The data collected for each patient are available during the life cycle of this clinical trial to fulfil an educational requirement (e.g. a doctoral thesis) upon request and authorization from the study committee and the study sponsor (GERCOR).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
* Written written non-opposition +/- signed informed consent for genetic studies (N.B.:
exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol
Exclusion Criteria
* Pregnant or breastfeeding women
* Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
* Refusal to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cindy Neuzillet, Dr
Role: PRINCIPAL_INVESTIGATOR
Institut Curie, Saint-Cloud
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Hôpital Sud Amiens
Amiens, , France
CHU Angers
Angers, , France
CHU Besançon
Besançon, , France
Hôpital Avicenne
Bobigny, , France
CHU - Henri Mondor
Créteil, , France
CHU Dijon
Dijon, , France
CHU Grenoble
Grenoble, , France
CHU Lille
Lille, , France
Centre Léon Bérard
Lyon, , France
Hôpital Croix Rousse
Lyon, , France
Hôpital Edouard Herriot
Lyon, , France
Hôpital Privé Jean Mermoz
Lyon, , France
Institut Paoli Calmette
Marseille, , France
CHU Saint Eloi Montpellier
Montpellier, , France
CHR Orléans
Orléans, , France
Groupe Hospitalier Pitié Salpêtrière
Paris, , France
Hôpital Ambroise Paré
Paris, , France
Hôpital Cochin
Paris, , France
Hôpital Saint Antoine
Paris, , France
Hôpital Saint Louis
Paris, , France
Institut Mutualiste Montsouris
Paris, , France
Hôpital Haut Lévêque
Pessac, , France
CHU Poitiers
Potiers, , France
Hôpital Robert Debré -CHU Reims
Reims, , France
Centre Eugène Marquis
Rennes, , France
CHU Rouen Charles Nicolle
Rouen, , France
Institut Curie
Saint-Cloud, , France
CHU Saint Etienne
Saint-Etienne, , France
CHU Rangueil
Toulouse, , France
CHU Tours
Tours, , France
CHRU Nancy Site Brabois
Vandœuvre-lès-Nancy, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Vincent HAUTEFEUILLE, MD
Role: primary
Carole VITELLIUS, MD
Role: primary
Angélique VIENOT, MD
Role: primary
Jean Charles NAULT, MD
Role: primary
Christophe TOURNIGAND, MD
Role: primary
Sylvain MANFREDI, MD
Role: primary
Gaël ROTH, MD
Role: primary
Anthony TURPIN, MD
Role: primary
Mathieu SARABI, MD
Role: primary
Marielle GUILLET, MD
Role: primary
Thomas WALTER, MD
Role: primary
Pascal ARTRU, MD
Role: primary
Brice CHANEZ, MD
Role: primary
Eric ASSENAT, MD
Role: primary
Jean Paul LAGASSE, MD
Role: primary
Jean Baptiste BACHET, MD
Role: primary
Aude GUILLEMIN, MD
Role: primary
Romain CORIAT, MD
Role: primary
Raphaël COLLE, MD
Role: primary
Nelson LOURENCO, MD
Role: primary
Christophe LOUVET, MD
Role: primary
Jean François BLANC, MD
Role: primary
David TOUGERON, MD
Role: primary
Alexandra HEURGUE, MD
Role: primary
Julien EDELINE, MD
Role: primary
Lilian SCHWARZ, MD
Role: primary
Cindy NEUZILLET, MD
Role: primary
Nicolas WILLET, MD
Role: primary
Nadim FARES, MD
Role: primary
Thierry LECOMTE, MD
Role: primary
Marie MULLER, MD
Role: primary
Antoine HOLLEBECQUE, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, Vernerey D, Vincens M, Chanez B, Tougeron D, Tournigand C, Assenat E, Delaye M, Manfredi S, Bouche O, Williet N, Vienot A, Blaise L, Mas L, Neuzillet C, Boileve A, Roth GS. First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort. JHEP Rep. 2024 Nov 20;7(2):101279. doi: 10.1016/j.jhepr.2024.101279. eCollection 2025 Feb.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACABi PRONOBIL GB-115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.